“Lower mortality rate, better clinical status, and shorter duration of invasive ventilation were observed in hospitalised patients with COVID-19 treated with imatinib during a 90-day follow-up” A long-term clinical outcomes analysis of COVID-19 patients treated with imatinib has recently been published in The Lancet Respiratory Medicine. The study, performed at VUmc, reviewed the 90-day outcomes […]
Author Archives: admin
“The Impentri IMI2 consortium are pleased to announce the first patients have been dosed in Amsterdam, NL as part of its clinical trial to investigate the safety and efficacy of intravenous imatinib mesilate (Impentri™) in subjects with Acute Respiratory Distress Syndrome induced by COVID-19” The trial is a Phase II, randomised, double-blind, placebo-controlled study being […]
Results published on Friday 18 June in The Lancet Respiratory Medicine show that oral imatinib, currently used to treat cancers, reduces mortality by 49% in hospitalized COVID-19 patients. The results of the world-first trial, led by VUmc, Amsterdam, could signify another option in the management of COVID-19 to protect lives The publication of the CounterCOVID […]
IMPENTRI will look for clinical proof of the benefit of imatinib in Covid-19 acute respiratory distress syndrome The build-up of fluid in the lungs is common among patients with severe cases of Covid-19 infection, and can lead to breathing problems and even death. It’s caused by the damage to cells that line the blood vessels […]
CAMBRIDGE, UK AND DUBLIN, IRELAND, May 13 2020 / / — Exvastat (Ireland) Ltd, a privately held biopharmaceutical company backed by Cambridge Innovation Capital, today announced the Innovative Medicines Initiative has through a highly competitive process awarded the company a €3.6m grant, following its call for developers to uncover a new use of the licensed […]